AU2010291927A1 - Methods for treating psoriasis - Google Patents

Methods for treating psoriasis Download PDF

Info

Publication number
AU2010291927A1
AU2010291927A1 AU2010291927A AU2010291927A AU2010291927A1 AU 2010291927 A1 AU2010291927 A1 AU 2010291927A1 AU 2010291927 A AU2010291927 A AU 2010291927A AU 2010291927 A AU2010291927 A AU 2010291927A AU 2010291927 A1 AU2010291927 A1 AU 2010291927A1
Authority
AU
Australia
Prior art keywords
antibody
population
subject
antigen
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010291927A
Other languages
English (en)
Inventor
Walid M. Awni
Yanjun Bao
William T. Barchuk
Elliot K. Chartash
William G. Glass
Kenneth B. GORDON
Yihua GU
Tom C. Harris
Martin Kaul
Parvez M. Mulani
Peter Noertersheuser
Martin M. Okun
Susan K. Paulson
Joaquin Mario Valdes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Deutschland GmbH and Co KG
AbbVie Inc
Original Assignee
AbbVie Deutschland GmbH and Co KG
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Deutschland GmbH and Co KG, AbbVie Inc filed Critical AbbVie Deutschland GmbH and Co KG
Publication of AU2010291927A1 publication Critical patent/AU2010291927A1/en
Priority to AU2013202866A priority Critical patent/AU2013202866A1/en
Assigned to ABBOTT GMBH & CO. KG, ABBVIE INC. reassignment ABBOTT GMBH & CO. KG Request for Assignment Assignors: ABBOTT GMBH & CO. KG, ABBOTT LABORATORIES
Assigned to AbbVie Deutschland GmbH & Co. KG, ABBVIE INC. reassignment AbbVie Deutschland GmbH & Co. KG Request for Assignment Assignors: ABBOTT GMBH & CO. KG, ABBVIE INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2010291927A 2009-09-14 2010-09-14 Methods for treating psoriasis Abandoned AU2010291927A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013202866A AU2013202866A1 (en) 2009-09-14 2013-04-08 Methods for treating psoriasis

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US24228809P 2009-09-14 2009-09-14
US61/242,288 2009-09-14
US24596709P 2009-09-25 2009-09-25
US61/245,967 2009-09-25
US29762310P 2010-01-22 2010-01-22
US61/297,623 2010-01-22
US36029910P 2010-06-30 2010-06-30
US61/360,299 2010-06-30
PCT/US2010/048771 WO2011032148A1 (en) 2009-09-14 2010-09-14 Methods for treating psoriasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013202866A Division AU2013202866A1 (en) 2009-09-14 2013-04-08 Methods for treating psoriasis

Publications (1)

Publication Number Publication Date
AU2010291927A1 true AU2010291927A1 (en) 2012-04-12

Family

ID=43732849

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010291927A Abandoned AU2010291927A1 (en) 2009-09-14 2010-09-14 Methods for treating psoriasis

Country Status (15)

Country Link
US (2) US8557239B2 (ru)
EP (1) EP2477654A4 (ru)
JP (1) JP2013504598A (ru)
KR (2) KR20140048229A (ru)
CN (1) CN102630168A (ru)
AU (1) AU2010291927A1 (ru)
CA (1) CA2773556A1 (ru)
IL (1) IL218633A0 (ru)
IN (1) IN2012DN01965A (ru)
MX (1) MX2012003138A (ru)
NZ (1) NZ598722A (ru)
RU (1) RU2012114854A (ru)
SG (1) SG179135A1 (ru)
TW (1) TW201127400A (ru)
WO (1) WO2011032148A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010315557B2 (en) * 2009-10-26 2014-02-27 Amgen Inc. Human IL-23 antigen binding proteins

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008088823A2 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
US8178092B2 (en) 2008-03-18 2012-05-15 Abbott Laboratories Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
SG189836A1 (en) * 2010-10-06 2013-06-28 Abbvie Inc Methods for treating psoriasis
CA2841970A1 (en) * 2011-07-13 2013-01-17 Abbvie Inc. Methods and compositions for treating asthma using anti-il-13 antibodies
AP2015008803A0 (en) * 2013-03-15 2015-10-31 Amgen Inc Methods for treating psoriasis using an anti-il-23antibody
BR112019005725A2 (pt) * 2016-09-23 2019-07-09 Abbvie Inc ajuste de dose
WO2019090329A1 (en) * 2017-11-06 2019-05-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
RU2697415C1 (ru) * 2018-11-12 2019-08-14 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Способ лечения каплевидного псориаза
JP2024510588A (ja) * 2021-03-12 2024-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体による、ｔｎｆ療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
BR112023018353A2 (pt) * 2021-03-12 2024-02-06 Janssen Biotech Inc Método seguro e eficaz para tratamento da artrite psoriática com anticorpo específico anti-il23

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3127158B2 (ja) 1989-10-05 2001-01-22 オプテイン，インコーポレイティド 新規の遺伝子及びポリペチドの無細胞合成並びに単離
US5780597A (en) 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
DE122009000074I1 (de) 1993-03-05 2011-12-01 Bayer Healthcare Ag Humane monoklonale anti-TNF alpha Antikorper.
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
EP0638644A1 (en) 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Receptors of interleukin-12 and antibodies
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
ZA95960B (en) 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5562138A (en) * 1994-10-13 1996-10-08 The Longaberger Company Bowing press
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
US5670057A (en) 1995-04-28 1997-09-23 Baxter International Inc. Apparatus and method for automatically performing peritoneal equilibration tests
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5853697A (en) 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US6297395B1 (en) 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000004I1 (de) 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
AU7257696A (en) 1996-10-11 1998-05-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
ATE256476T1 (de) 1996-11-15 2004-01-15 Kennedy Inst Of Rheumatology Unterdrückung von tnfalpha und il-12 in der therapie
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6054487A (en) 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
EP1049717B1 (en) 1998-01-23 2007-03-21 F. Hoffmann-La Roche Ag Antibodies against human il-12
US20020161199A1 (en) 1998-04-08 2002-10-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
WO2000034459A1 (en) 1998-12-09 2000-06-15 Protein Design Labs, Inc. Animal model for psoriasis for the prevention and treatment of psoriasis in humans
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
BR0009323A (pt) * 1999-03-25 2002-01-08 Knoll Gmbh Anticorpos humanos que ligam a il-12 humana e métodos para a produção
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US8080247B2 (en) * 2000-08-07 2011-12-20 Janssen Biotech, Inc. Anti-IL-12 antibodies
WO2002098445A1 (en) 2001-05-30 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Protein preparation
WO2004007520A2 (en) 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US7608260B2 (en) 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
EP1698640B2 (en) 2003-10-01 2019-06-19 Kyowa Hakko Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation
AU2004298393A1 (en) 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
AU2005211890B2 (en) 2004-02-12 2011-07-28 Merck Patent Gmbh Highly concentrated liquid formulations of anti-EGFR antibodies
WO2007005955A2 (en) 2005-06-30 2007-01-11 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
WO2008088823A2 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
US8178092B2 (en) 2008-03-18 2012-05-15 Abbott Laboratories Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
KR20110096553A (ko) 2008-11-28 2011-08-30 아보트 러보러터리즈 안정한 항체 조성물 및 이의 안정화 방법
SG189836A1 (en) 2010-10-06 2013-06-28 Abbvie Inc Methods for treating psoriasis
TW201309330A (zh) 2011-01-28 2013-03-01 Abbott Lab 包含糖基化抗體之組合物及其用途

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010315557B2 (en) * 2009-10-26 2014-02-27 Amgen Inc. Human IL-23 antigen binding proteins
US9951129B2 (en) 2009-10-26 2018-04-24 Amgen Inc. Human IL-23 antigen binding proteins
US12012449B2 (en) 2009-10-26 2024-06-18 Amgen Inc. Human IL-23 antigen binding proteins

Also Published As

Publication number Publication date
NZ598722A (en) 2014-05-30
EP2477654A4 (en) 2013-01-23
KR20140048229A (ko) 2014-04-23
JP2013504598A (ja) 2013-02-07
IN2012DN01965A (ru) 2015-08-21
IL218633A0 (en) 2012-05-31
US8557239B2 (en) 2013-10-15
CN102630168A (zh) 2012-08-08
US20140079714A1 (en) 2014-03-20
US20110206680A1 (en) 2011-08-25
RU2012114854A (ru) 2013-10-27
CA2773556A1 (en) 2011-03-17
TW201127400A (en) 2011-08-16
EP2477654A1 (en) 2012-07-25
MX2012003138A (es) 2012-07-04
WO2011032148A1 (en) 2011-03-17
SG179135A1 (en) 2012-05-30
KR20120112384A (ko) 2012-10-11

Similar Documents

Publication Publication Date Title
US8178092B2 (en) Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
AU2010291927A1 (en) Methods for treating psoriasis
US7776331B1 (en) Methods of treating plaque psoriasis
US20120189637A1 (en) Methods for treating psoriasis
US20140093516A1 (en) Human antibodies that bind the p40 subunit of human il-12/il-23 and uses therefor
AU2013202866A1 (en) Methods for treating psoriasis
AU2013202860A1 (en) Methods for treating psoriasis
AU2013203142A1 (en) Methods for treating psoriasis
AU2013202849A1 (en) Methods for treating psoriasis

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ABBOTT GMBH & CO. KG; ABBVIE INC.

Free format text: FORMER APPLICANT(S): ABBOTT LABORATORIES; ABBOTT GMBH & CO. KG

PC1 Assignment before grant (sect. 113)

Owner name: ABBVIE INC.; ABBVIE DEUTSCHLAND GMBH & CO. KG

Free format text: FORMER APPLICANT(S): ABBVIE INC.; ABBOTT GMBH & CO. KG

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted